[Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B].

Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, Zhao YX, Wang PJ

Zhonghua zhong liu za zhi [Chinese journal of oncology]1 Feb 2005Cited by 5 (Europe PMC)

PMID15946554PepBankPUB-15946554

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In patients with hepatocellular carcinoma and active hepatitis B, postoperative lamivudine plus thymosin alpha1 raised the 1-year HBV-DNA suppression rate versus hepatectomy only.
In plain wordsIn patients with liver cancer and active hepatitis B, lamivudine plus thymosin alpha‑1 after surgery gave more hepatitis B virus suppression than surgery alone.
Peptide
Thymosin alpha-1
Outcome
Increase1-year HBV-DNA suppression rate
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Antiviral activity · Liver
Measurements
1-year HBV-DNA suppression rate
100%
Group II
1-year HBV-DNA suppression rate
6%
Group I
Source sentences
Summary
the 1-year HBV-DNA suppression rate was 100.0% vs 6.0% (P < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 HCC patients with coexisting with active hepatitis B were randomized into two groups: Group I (n = 17) received hepatectomy only, and Group II (n = 16) received hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1594655401
02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In patients with hepatocellular carcinoma and active hepatitis B, postoperative lamivudine plus thymosin alpha1 raised the HBeAg seroconversion rate versus hepatectomy only.
In plain wordsIn patients with liver cancer and active hepatitis B, lamivudine plus thymosin alpha‑1 after surgery gave more HBeAg seroconversion than surgery alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseHBeAg seroconversion rate
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Antiviral activity · Liver
Measurements
HBeAg seroconversion rate
62.5%
Group II
HBeAg seroconversion rate
5.9%
Group I
Source sentences
Summary
HBeAg seroconversion rate was 62.5% vs 5.9% (P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 HCC patients with coexisting with active hepatitis B were randomized into two groups: Group I (n = 17) received hepatectomy only, and Group II (n = 16) received hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1594655402
03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In patients with hepatocellular carcinoma and active hepatitis B, the tumor recurrence rate did not differ significantly between postoperative lamivudine plus thymosin alpha1 and hepatectomy only.
In plain wordsIn patients with liver cancer and active hepatitis B, lamivudine plus thymosin alpha‑1 after surgery did not significantly change cancer recurrence versus surgery alone.
Peptide
Thymosin alpha-1
Outcome
No significant changeTumor recurrence rate
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Tumor growth · Cancer
Measurements
Tumor recurrence rate
81.3%
Group II
Tumor recurrence rate
95.5%
Group I
Source sentences
Summary
tumor recurrence rate was 81.3% vs 95.5% (P > 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 HCC patients with coexisting with active hepatitis B were randomized into two groups: Group I (n = 17) received hepatectomy only, and Group II (n = 16) received hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1594655403
04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In patients with hepatocellular carcinoma and active hepatitis B, postoperative lamivudine plus thymosin alpha1 lengthened the time to recurrence versus hepatectomy only.
In plain wordsIn patients with liver cancer and active hepatitis B, lamivudine plus thymosin alpha‑1 after surgery delayed cancer recurrence compared with surgery alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseRecurrence time
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Tumor growth · Cancer
Measurements
Recurrence time
7 months
Group II
Recurrence time
5 months
Group I
Source sentences
Summary
the recurrence time was 7.0 vs 5.0 months (P < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 HCC patients with coexisting with active hepatitis B were randomized into two groups: Group I (n = 17) received hepatectomy only, and Group II (n = 16) received hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1594655404
05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In patients with hepatocellular carcinoma and active hepatitis B, postoperative lamivudine plus thymosin alpha1 lengthened median survival versus hepatectomy only.
In plain wordsIn patients with liver cancer and active hepatitis B, lamivudine plus thymosin alpha‑1 after surgery was linked to longer survival than surgery alone.
Peptide
Thymosin alpha-1
Outcome
IncreaseMedian survival
Study
n = 33
Comparator
Hepatectomy only
Outcome group
Mortality · Cancer
Measurements
Median survival
10 months
Group II
Median survival
7 months
Group I
Source sentences
Summary
median survival 10.0 vs 7.0 months (P < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
2002, 33 HCC patients with coexisting with active hepatitis B were randomized into two groups: Group I (n = 17) received hepatectomy only, and Group II (n = 16) received hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1.
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1594655405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.